Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

6 days ago
Long-term treatment with memantine is well tolerated but does not effectively prevent glaucomatous progression in patients with open-angle glaucoma (OAG), according to the results of two phase III trials.
Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Radha Chitale, 06 Apr 2016
Results from a trio of papers detailing the Heart Outcomes Prevention Evaluation (HOPE)-3 trial demonstrated that cholesterol-lowering statin therapy plus two blood pressure drugs reduced the risk of cardiovascular events in intermediate risk patients with average cholesterol and blood pressure levels.

Linezolid enhances early outcome of childhood tuberculous meningitis

01 Jun 2016
Linezolid is associated with early outcome improvements in childhood tuberculous meningitis patients, as shown in a retrospective review. Low adverse effect frequency was reported with linezolid.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

6 days ago
Long-term treatment with memantine is well tolerated but does not effectively prevent glaucomatous progression in patients with open-angle glaucoma (OAG), according to the results of two phase III trials.
Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Radha Chitale, 06 Apr 2016
Results from a trio of papers detailing the Heart Outcomes Prevention Evaluation (HOPE)-3 trial demonstrated that cholesterol-lowering statin therapy plus two blood pressure drugs reduced the risk of cardiovascular events in intermediate risk patients with average cholesterol and blood pressure levels.